Plasma lncRNA Biomarkers for Early MCI Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Alzheimer's disease and mild cognitive impairment are time-consuming, labor-intensive, and lack effective peripheral blood biomarkers for early detection, relying on expensive and inaccessible imaging techniques.
Innovation Solution
Development of a diagnostic marker using specific long non-coding RNA (lncRNA) molecules, such as ENST000000549762, NR_024049, and ENST000000567919, in plasma for screening and diagnosing mild cognitive impairment, integrated into a diagnostic kit for measuring their expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If professional doctors use medical history consultation and scale scores for diagnosis, then diagnostic accuracy can be maintained, but the evaluation becomes time-consuming and labor-intensive
Solution Approach 1:
The patent performs preliminary screening using lncRNA biomarker detection in peripheral blood before comprehensive clinical evaluation. This preliminary action identifies high-risk individuals who then receive full diagnostic workup, reducing the time and resources needed for population-wide screening while maintaining diagnostic accuracy for those who need it.
Solution Approach 2:
The patent introduces lncRNA biomarkers as an intermediary between initial patient presentation and full clinical diagnosis. These biomarkers serve as a mediator that provides objective, quantifiable data to support clinical judgment, reducing the time required for subjective scale assessment while maintaining or improving diagnostic accuracy.
2Measurement precision
If brain structure imaging examination is used for auxiliary diagnosis, then macroscopic brain structure changes can be observed, but it cannot detect early stage MCI characteristic changes and is expensive
Solution Approach 1:
The patent employs peripheral blood samples as a cheap, easily obtainable biological material instead of expensive brain imaging. The blood-based lncRNA detection provides a low-cost alternative that can be performed repeatedly over time to track disease progression, making early detection accessible without the high costs of MRI or PET imaging.
Solution Approach 2:
The patent substitutes mechanical/physical imaging methods (MRI, CT, PET) with a biochemical detection method based on lncRNA analysis. This replacement uses molecular biology techniques to detect disease-related RNA molecules in blood, achieving early detection capability without the expense and complexity of advanced imaging equipment.
3Measurement precision
If senile plaque imaging is used for AD diagnosis, then pathological changes can be visualized, but it is expensive and has no clinical application in China
Solution Approach 1:
The patent extracts the diagnostic function from complex, expensive imaging procedures and concentrates it into a simple blood test. By taking out the essential diagnostic information (presence of disease markers) and delivering it through a minimal-invasive blood sample analysis, the patent makes accurate diagnosis accessible in routine clinical settings without requiring specialized imaging facilities.
Solution Approach 2:
The patent creates a functional copy of the diagnostic capability found in expensive imaging procedures. Instead of requiring actual PET or MRI scans to detect pathological changes, the patent uses lncRNA biomarkers in blood as a surrogate indicator that copies the diagnostic information, providing equivalent clinical value at a fraction of the cost and with much greater accessibility.
4Ease of operation
If peripheral blood biomarkers are used for screening, then early diagnosis can be achieved with simple operation and minimal trauma, but no effective biomarkers have been identified yet
Solution Approach 1:
The patent uses a composite approach by analyzing multiple lncRNA biomarkers simultaneously rather than relying on a single marker. This composite biomarker panel combines several RNA molecules with different expression patterns, creating a more robust and accurate diagnostic tool that overcomes the limitations of individual markers while maintaining the simplicity of blood-based testing.
Data Source
AI summary
A diagnostic marker for prodromal stage Mild Cognitive Impairment (MCI) of the Alzheimer's disease is provided. The marker is plasma long-chain non-coding ribonucleic acid (lncRNA), including one or more of ENST00000549762, NR_024049, T324988 or ENST00000567919. Also disclosed are an application of the marker and a corresponding kit.